Phenylbutazone and hepatitis.
During a comparative trial  between enteric-coated and rectally administered phenylbutazone in patients with rheumatoid disease, one patient developed a mild hepatitis. She had recently concluded a long period of gold therapy. The natural history of phenylbutazone hepatitis is reviewed on the basis of 41 case histories, and the experience with this individual patient interpreted accordingly.
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000276:immunology; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008111:Liver Function Tests; D008213:Lymphocyte Activation; D010653:Phenylbutazone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013488:Suppositories; D013608:Tablets, Enteric-Coated
D013488:Suppositories; D013608:Tablets, Enteric-Coated; D010653:Phenylbutazone